Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target.

Protein kinases are central targets for drug-based cancer treatment. To avoid functional impairment, the cell develops mechanisms of drug resistance, primarily based on adaptive mutations. Redesigning a drug to target a drug-resistant mutant kinase constitutes a therapeutic challenge. We approach the problem by redesigning the anticancer drug imatinib guided by local changes in interfacial de-wetting propensities of the C-Kit kinase target introduced by an imatinib-resistant mutation. The ligand is redesigned by sculpting the shifting hydration patterns of the target. The association with the modified ligand overcomes the mutation-driven destabilization of the induced fit. Consequently, the redesigned drug inhibits both mutant and wild-type kinase. The modeling effort is validated through molecular dynamics, test tube kinetic assays of downstream phosphorylation activity, high-throughput bacteriophage-display kinase screening, cellular proliferation assays, and cellular immunoblots. The inhibitor redesign reported delineates a molecular engineering paradigm to impair routes for drug resistance.

[1]  Ariel Fernández,et al.  Keeping dry and crossing membranes , 2004, Nature Biotechnology.

[2]  Peter J. Rossky,et al.  Surface topography dependence of biomolecular hydrophobic hydration , 1998, Nature.

[3]  P. Besmer,et al.  Kit signaling through PI 3‐kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation , 1998, The EMBO journal.

[4]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[5]  Y. Suzuki,et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[6]  B. Druker,et al.  Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). , 2002, Cancer research.

[7]  C. Bokemeyer,et al.  Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. , 2006, Cancer research.

[8]  M. Mareel,et al.  The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. , 2002, Cancer research.

[9]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[10]  F. Lee,et al.  Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. , 2006, Blood.

[11]  R. DeMatteo.  The GIST of targeted cancer therapy: A tumor (Gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571) , 2002, Annals of Surgical Oncology.

[12]  G. Dewald,et al.  Establishment of an immature mast cell line from a patient with mast cell leukemia. , 1988, Leukemia research.

[13]  Ioan Andricioaei,et al.  On the calculation of entropy from covariance matrices of the atomic fluctuations , 2001 .

[14]  Ariel Fernández,et al.  Rational Drug Redesign to Overcome Drug Resistance in Cancer Therapy: Imatinib Moving Target , 2008 .

[15]  B. Druker,et al.  Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. , 2004, Blood.

[16]  B. Druker.  Circumventing resistance to kinase-inhibitor therapy. , 2006, The New England journal of medicine.

[17]  P. Kollman,et al.  Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. , 2001, Journal of the American Chemical Society.

[18]  Li Fang,et al.  p53 induction and activation of DDR1 kinase counteract p53‐mediated apoptosis and influence p53 regulation through a positive feedback loop , 2003, The EMBO journal.

[19]  J. Li.  Contemporary Drug Synthesis , 2004 .

[20]  振津 琢磨.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product , 1995 .

[21]  K. Wilson,et al.  Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase* , 2004, Journal of Biological Chemistry.